Type I IFN Receptor Knockout Immortalized Mouse Dendritic Cell Line

CAT.NOUNITPRICE
T30361x106 cells / 1.0 ml
$0.00

Specifications


DescriptionAs messengers bridging the innate and adaptive immune system, the conventional tissue-resident DC (cDC) acts as sentinels in secondary lymphoid organs and other tissues for antigen capture and presentation. The MutuDC1IFNR -/-) cell line is an immortalized splenic CD8α subset (CD11chigh,B220-,DEC205 ,CD24high,CD11b-) of conventional dendritic cells derived from the 1IFNR knockout CD11c:SV40LgT transgenic mice.

Like the Wild-type MutuDC cell line (Cat. No. T0528), the MutuDC1IFNR -/- cell line retains response to TLR ligands such as CpG (TLR9-L) and PolyIC (TLR3-L) and to a lesser extent LPS (TLR4-L) stimulation by up-regulation of co-stimulatory molecules CD40, CD80 and CD86. In addition to responding to PAMP stimulation and producing Th1 cytokines such as IL-12, these cells are also capable of presenting antigen in the context of both MHC-I and MHC-II, including direct antigen presentation and cross-presentation of cell-associated antigens. Studies has shown that several genes were found to be differentially negatively (Tnfa and Pdl1) or positively (Ifnb, Il10, and Ccr7) upregulated in the MutuDC1IFNR -/- cells upon stimulation. Together with TLR3 knockout (Cat. No. T3034) and TLR9 knockout (Cat. No. T3035) MutuDC, these dendritic cell lines provide a powerful tool in vaccine science and immunotherapy, particularly in strategizing target antigens to CD8α subset.
SKUT3036
SpeciesMouse (M. musculus)
Species descriptionMouse (C57BL/6J)
Tissue/Organ/Organ SystemSpleen
Growth PropertiesAdherent
Cell MorphologySmall Aggregates
Seeding Density2.5 x 105 cells/cm2, should not be split lower than 5 x 104 cells per cm2
ApplicationsFor Research Use Only
Unit quantity1x106 cells / 1.0 ml
Pharmaceutical TargetCatalytic Receptors
CautionFor Research Use Only
Cell TypeDrug Discovery Cells
Expression ProfileCD11c, CD24, MHC-II+, DEC205, Clec9A, B220, CD11b, IRF4, IRF8, CD4
Propagation Requirements
Use of PriCoatTMT25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) is required for cell adhesion to the culture vessels. Grow cells inECM-coated culture vessels unless otherwise specified in the Propagation Requirements below.
The base medium for this cell line is PriGrow V available at abm (TM015). To make the completed growth medium, add the following components to the base medium: 10% decomplemented fetal calf serum (PAN biotech; P40-37500), 50 μM ?-mercaptoethanol, 1% HEPES, and Penicillin/Streptomycin Solution (G255) to a final concentration of 1%. Stimulation can be performed using CpG (2 mM) or LPS (5 μg/ml).
Carbon dioxide (CO2): 5%, Temperature: 37.0°C.

IMPORTANT: This cell line is very sensitive to FBS batches. We strongly recommend end users to use FBS obtained from PAN biotech.
Preservation Protocol1. Freeze Medium: Complete growth medium with 50% decomplemented fetal calf serum (PAN biotech; P40-37500) and 10% DMSO.

2. Storage Temperature: Liquid nitrogen vapour phase.
QC1) Direct antigen presentation and cross-antigen presentation were evaluated by the MHC-I (SIINFEKL/OT-I ) and MHC-II (OVA323-339/OT-II) restricted systems; 3) proteome profile and surface markers assessed by RT-PCR; RT-PCR; 3) IL-12 cytokine secretion analyzed using ELISA ; 4) Response to PAMP stimulation evaluated by functional assays.
Disclaimer

1. For for-profit organizations and corporations, please contact [email protected] for pricing of this item.

2. Sale of this item is subjected to the completion of a Material Transfer Agreement (MTA) by the purchasing individual/institution for each order. If you have any questions regarding this, please contact us at [email protected].

3. All test parameters provided in the CoA are conducted using abm's standardized culture system and procedures. The stated values may vary under the end-user's culture conditions. Please verify that the product is suitable for your studies by referencing published papers or ordering RNA (0.5 μg, Cat.# C207, $450.00) or cell lysate (100 μg, Cat.# C206, $600.00) to perform preliminary experiments, or alternatively use our Gene Expression Assay Service (Cat# C138). All sales are final.

4. We recommend live cell shipments for ease of cell transfer and this option can be requested at the time of ordering. Please note that the end-user will need to evaluate the feasibility of live cell shipment by taking into account the final destination's temperature variation and its geographical location. In addition, we thoroughly test our cell lines for freeze-thaw recovery. If frozen cells were received and not recovered in your lab under the exact, specified conditions (using recommended culture vessel, media, additional supplements, and atmospheric conditions), a live cell replacement is possible at a cost (plus shipping).

5. All of abm's cell biology products are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its cell biology product(s) in therapeutic/diagnostic application(s). Please contact a technical service representative for more information.

6. abm makes no warranties or representations as to the accuracy of the information on this site. Citations from literature and provided for informational purposes only. abm does not warrant that such information has been shown to be accurate.

7. abm warrants that cell lines shall be viable upon initiation of culture for a period of thirty (30) days after shipment and that they shall meet the specifications on the applicable abm Material Product Information sheet, certificate of analysis, and/or catalog description. Such thirty (30) day period is referred to herein as the "Warranty Period."

DepositorUniversity of Lusanne
Documents


Supporting Protocol
MSDS

    QC

      Other

      FAQs


      There are no FAQs for this product yet!
      References


      1
      • Fuertes Marraco, SA et al. "Novel murine dendritic cell lines: a powerful auxiliary tool for dendritic cell research" Front Immunol. 3:331 (2012). DOI: 10.3389/fimmu.2012.00331.